A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Food Effects of a Single Oral VV119 Capsule in Healthy Chinese Volunteers
Latest Information Update: 19 Feb 2025
At a glance
- Drugs VV 119 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Vigonvita Life Sciences
- 11 Feb 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 11 Feb 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 08 May 2024 Planned End Date changed from 1 Apr 2024 to 1 Dec 2024.